Navigation Links
COX-2 inhibitors Lessen Breast Cancer Risk

Selective usage of COX-2 inhibitors like rofecoxib (Vioxx) and celecoxib (Celebrex) reduces breast cancer risk by 71%, according to a study. The Ohio State University College of Medicine and Public Health's Randall Harris led the // research which came to this conclusion. The nonsteroidal anti-inflammatory drugs (NSAIDs) play a prominent role in the prevention of breast cancer.

The researchers observed that while daily use of selective COX-2 inhibitors was associated with a 71% reduction in the risk of breast cancer, non-selective COX-2 inhibitors, such as aspirin and ibuprofen, also reduced the risk of breast cancer. The study's results show that selective COX-2 inhibitors, as a group, were associated with a significantly reduced risk of breast cancer when taken daily for at least two years.

While a daily dose of 200 mg celecoxib reduced the risk of breast cancer by 83%, a daily dose of 25 mg rofecoxib reduced the risk of breast cancer by 64%. Regular use of non-selective COX-2 inhibitors like aspirin (325 mg), ibuprofen (200mg) and naproxen (250 mg) also significantly reduced the risk of breast cancer, but less so than the regular intake of selective COX-2 inhibitors. It was found that Ibuprofen and aspirin significantly decreased the risk of developing breast cancer when taken at least every other day for at least five years.

However, the researchers also found that regular intake of acetaminophen, an analgesic lacking COX-2 activity, had no effect on the risk of breast cancer. The study is published in the open access journal BMC Cancer.

Edited (ANI)
'"/>




Page: 1

Related medicine news :

1. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
2. Phase 3 trials of two multi-kinase inhibitors against cancer
3. Lessening operation and recovery time
4. Physical Exertion Can Lessen Depression
5. Risk Of Stroke Can Be Lessened By Proper Diet
6. Fatigue After Liver Transplantation Does Not Lessen With Time
7. Vulnerability to Ear Infections Lessened by Breast Feeding
8. A Discovery That may Lessen a Health Disparity
9. Consensus on "Combination Therapy" for Breast Cancer
10. Breast cancer treatment to be determined by gene test
11. Breast Feeding prevents obesity later on in life
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... ... Usually, the impending arrival of warmer weather means the gleeful banishment of ... chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic Laser ... chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the fat ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of two biometric time and attendance tracking products: the new NCheck Cloud ... NCheck Cloud Bio Attendance uses biometric face recognition to enable users to check ...
(Date:3/28/2017)... ... ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio and New ... sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National Advisory Board., ... the clinic from a small start-up to number 78 in the country based on ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice ... Atlantic City March 13-16, was a busy spot this year. Liz Solovay and ... strategies for preventing outbreaks among camp communities during the upcoming 2017 camping season. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Nurse practitioners ... as their value increases in the healthcare workforce, according to a survey recently ... boards, career fairs, and candidate leads to healthcare employers of physicians and advanced ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Israel , March 28, 2017 Emosis ... This new business entity, Emosis Ltd, headquartered in Tel ... of novel assays complementing the mother company existing technology platform and ... and sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. ...
(Date:3/28/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a ... commercialization of innovative therapies for the treatment of ... Agency (EMA) has notified the company that the ... Application (MAA) has passed validation, and that the ... MAA for ARX-04 (known as DSUVIA™ in the ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
Breaking Medicine Technology: